Skip to main content
Article
Concurring hypertrophic cardiomyopathy and takotsubo cardiomyopathy: Assessment and management
All Scholarly Works
  • Mohammed Abozenah, Baystate Health
  • Anis Kadado, MD, Baystate Health
  • Khalid Sawalha, MD, Baystate Health
  • Colby Salerno, DO, Baystate Health
  • Ayman Battisha, MD, Baystate Health
  • Amir Lotfi, Baystate Health
Document Type
Article, Peer-reviewed
Publication Date
10-1-2020
Abstract

The prevalence of takotsubo cardiomyopathy (TCM) has been on the rise, but co-occurrence with hypertrophic cardiomyopathy (HOCM) remains rare. Although presenting patient demographics were similar to those in TCM, the potential for hemodynamic compromise was significantly compounded by the presence of underlying HOCM. Management was similar to standalone TCM, although use of inotropic agents and mechanical support appears to be more prevalent. Despite the increased potential for complications and the paucity of data regarding management, outcomes appear to be mostly favorable in both the hospitalization period and at follow-up. Interestingly, despite a new diagnosis of HOCM in about half the cases described, which signifies no significant left ventricular outflow tract (LVOT) gradient prior to TCM, half of those patients had a persistently elevated LVOT gradient after resolution of TCM. This poses a question of whether or not TCM can predispose to LVOT obstruction in HOCM patients even after its resolution.

Keywords: Hypertrophic cardiomyopathy; Left ventricular outflow tract obstruction; Left ventricular outflow tract peak gradient; Shock; Takotsubo cardiomyopathy.

PMID
33143911
Citation Information
Abozenah M, Kadado AJ, Aljamal A, Sawalha K, Salerno C, Battisha A, Hernandez-Montfort J, Lotfi A. Concurring hypertrophic cardiomyopathy and takotsubo cardiomyopathy: Assessment and management. Heart Lung. 2020 Oct 31:S0147-9563(20)30396-4. doi: 10.1016/j.hrtlng.2020.10.006. Epub ahead of print.